Table 3: Efficacy.
|
Response to treatment YES (CR, PR, SD) NO (DP) |
65 (90%) 8 (10%) |
40 (93%) 7 (17%) |
0.357 |
|
Progression YES NO |
60 (82%) 13 (18%) |
40 (85%) 7 (15%) |
0.439 |
|
Second line YES NO |
33 (45%) 40 (55%) |
17 (36%) 30 (64%) |
0.215 |
|
SECOND LINE Docetaxel Pemetrexed Erlotinib Others |
33 16 7 7 3 |
17 8 4 3 2 |
0.861 0.809 |
|
Situation at last follow up Alive without disease Alive with disease Dead with disease Dead without disease |
1 (1%) 14 (20%) 58 (79%) 0 |
0 7 (15%) 40 (85%) 0 |
0.590 0.494 |
CR: Complete Response; PR: Partial Response; SD:
Stable Disease; PD: Disease Progression